Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Overview of attention for article published in Investigational New Drugs, August 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

patent: 3 patents

Readers on

mendeley: 94 Mendeley

Summary Patents

So far, Altmetric has seen 3 patents that reference this research output.

Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for…

Grant US-11235037-B2

United States of America

Antibodies to argininosuccinate synthase and related methods

Grant US-9938355-B2

United States of America

ANTIBODIES TO ARGININOSUCCINATE SYNTHASE AND RELATED METHODS

Application EP-3166972-A4

European Patent Office

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.